Amgen melanoma drug shrinks tumors but fails secondary study goal

April 4, 2014 2:06 PM

16 0

(Reuters) - Amgen Inc said its experimental drug to treat a deadly form of skin cancer shrank tumors, but did not significantly improve overall survival rates in patients enrolled in a late-stage study.

The most common serious adverse events observed in the trial include disease progression, a bacterial skin infection and fever, the company said.

Read more

To category page